Discover Nolato’s strategic focus, financial flexibility for growth and attractive dividends.
Discover Nolato’s strategic focus, financial flexibility for growth and attractive dividends.
The Board of Nolato has 2025-03-13 established the following financial targets:
The target for the EBITA margin is to exceed 10% over a business cycle.
The target is to achieve cash conversion of more than 75% of EBIT over a business cycle, measured as the ratio of cash flow after investments and EBIT.
The target for the equity/assets ratio is to exceed 35% over a business cycle.
Nolato aims to achieve growth that exceeds the level of growth within each market segment.
Medical Solutions sales totaled SEK 5,434 million (5,308); adjusted for currency and acquisitions, sales grew by 2%. The Drug delivery market area and In vitro diagnostics (IVD) displayed growth, while
pharmaceutical packaging had lower volumes.
Engineered Solutions sales were SEK 4,243 million (4,245); adjusted for currency and acquisitions, sales were unchanged. The Materials (EMC) market area exhibited strong growth, increasing by 10%, adjusted for currency and acquisitions. The Hygiene and other market area also showed good growth, while Consumer electronics displayed a sharp drop in volumes.
Nolato’s dividend policy is to propose a dividend that exceeds 50% of profit after tax, taking account of Nolato’s long-term development opportunities, financial position and investment needs. The Board’s proposed dividend for 2025 is SEK 1.50 per share, which equates to 61% of profit after tax.